Steviol glycosides

Steviol Glycosides

1. Identity: Botanical Source, Chemical Classification, and Common Forms

Steviol glycosides are the chemical compounds responsible for the sweet taste of the leaves of the South American plant Stevia rebaudiana (Asteraceae), and the main ingredients (or precursors) of many sweeteners marketed under the generic name stevia and several trade names. Stevia rebaudiana (Bertoni) Hemsl., also known as honey chrysanthemum and stevia grass, is a dicotyledonous perennial herb of the Asteraceae family, native to Paraguay and Brazil in South America. Steviol glycosides also occur in the related species S. phlebophylla (but in no other species of Stevia) and in the plant Rubus chingii (Rosaceae).

Only 18 of the 150–300 species from the genus Stevia exhibit sweetening properties, and among them Stevia rebaudiana is the sweetest variety. The eight steviol glycosides (ent-kaurene glycosides), including dulcoside A, rebaudiosides A–E, steviolbioside, and stevioside, naturally occur in its leaves. Their total content oscillates from 4% to 20% depending on genotype and culture conditions.

To date, sixty-four steviol glycosides and more than thirty sweet flavor components have been isolated from stevia leaves. The contents of the main components are as follows: stevioside (5%–10%), rebaudioside A (2%–5%), rebaudioside C (~1%), glucoside A (~0.5%), rebaudiosides D, E, and F (~0.2%), and stevia disaccharide glycosides (~0.1%).

Chemical Structure

Steviol glycosides are terpene glycoside natural products, a class of steviol tetracyclic diterpene glycoside compounds formed by stevia (steviol) in the structure at the C-13 position or C-19 position through β-bonding. The major steviol glycoside in stevia leaves used in the food industry is rebaudioside A, containing four glucose residues. Stevioside, a tri-glucosylated steviol, is a precursor of rebaudioside A. The leaves contain a complex profile of diterpene glycosides, primarily stevioside (STE) and various rebaudiosides (e.g., Reb A, Reb D, Reb M), which are all derivatives of a common steviol aglycone backbone.

Physical and Chemical Properties

Steviol glycosides from Stevia rebaudiana have been reported to be between 30 and 320 times sweeter than sucrose, although there is some disagreement in the technical literature about these numbers. They are heat-stable, pH-stable, and do not ferment. Their taste has a slower onset and longer duration than that of sugar, and at high concentrations some extracts may have an aftertaste described as licorice-like or bitter. One of the main obstacles for the successful commercialization of stevia sweeteners, especially in food, is their slight bitter aftertaste and astringency.

Common Preparations and Forms

Steviol glycosides are commercially available in several forms:

• Dried leaf powder: Dry stevia leaves have been used to sweeten traditional bitter drinks such as mate tea.
• Purified extracts: In the United States, extracts of certain high-purity steviol glycosides have been generally recognized as safe (GRAS) and may be lawfully marketed and added to food products, but stevia leaf and crude extracts do not have GRAS or Food and Drug Administration (FDA) approval for use in food.
• Fermentation-derived forms: Newer production processes yield steviol glycosides by fermentation of simple sugars using genetically modified microorganisms.
• Glucosylated preparations: Glucosylated steviol glycoside preparations are described as a mixture of glucosylated steviol glycosides, containing 1–20 additional glucose units bound to the parent steviol glycoside via α-(1–4) linkages.

Beyond steviol glycosides, stevia leaves are a rich source of bioactive secondary metabolites, including flavonoids, phenolic acids like chlorogenic acid, and essential oils, which contribute to its potent antioxidant capacity.

2. Traditional and Historical Use

The plant Stevia rebaudiana has been used for centuries by the Guaraní peoples of South America, who called it ka'a he'ê ("sweet herb"). The leaves have been used traditionally for hundreds of years in both Paraguay and Brazil to sweeten local teas, and as a "sweet treat."

The Guaraní commonly used the leaves of the wild stevia shrub — a perennial indigenous to the Amambay Mountain region — to enhance the taste of bitter mate (a tea-like beverage) and medicinal potions, or simply chewed them for their sweet taste. These practices were noted by Spanish colonizers as early as the 16th century, suggesting a deep-rooted cultural reliance on the plant.

Guaraní people have long used its licorice-flavored leaves as a medicinal herb to regulate blood sugar. As historians Bridget Maria Chesterton and Timothy Yang have written, "It was, in other words, a diabetes medicine before diabetes had become a modern disease."

In 1887, Italian-Swiss botanist Moisés Santiago Bertoni began exploring the forests of eastern Paraguay, where local guides introduced him to Stevia rebaudiana and its remarkable properties. Bertoni conducted systematic studies on the plant, formally describing it and noting its exceptional sweetness in detail by 1901, which marked the modern scientific recognition of its potential as a sweetening agent. He named the species Stevia rebaudiana in 1905, honoring chemist Ovidio Rebaudi.

Japan was the first nation outside of Latin America to cultivate and market stevia as a sucrose alternative. China, Malaysia, Singapore, South Korea, Taiwan, and Thailand also began merchandising it. Stevia plantations can now be found in Southeast Asia, the U.S., Canada, and Europe.

3. Key Constituents and Active Compounds

Major Glycosides

The main sweet components of steviol glycosides are stevioside (Stv) and rebaudioside A (Reb A). Stevioside and rebaudioside A are the most abundant and have the best characterized sweetness profiles. Beyond these dominant glycosides, numerous minor rebaudiosides — including Reb B, C, D, E, F, and M — have been identified and are of increasing commercial interest.

A novel steviol glycoside, rebaudioside D17, has recently been identified from the leaf extract of Stevia rebaudiana Bertoni. This compound features a rare β-1→4 glycosidic linkage between two glucose units at the C-19 position, distinguishing it from its structural isomer, rebaudioside D. The discovery of rebaudioside D17 expands the known diversity of steviol glycosides and provides new insights into glycosylation patterns in Stevia rebaudiana, which may support the development and production of novel sweeteners with improved sensory and physicochemical properties.

Other Bioactive Constituents

The leaves of Stevia rebaudiana are rich in steviol glycosides, protein, fiber, amino acids, lipids, carotenoids, ascorbic acid, and bioactive compounds. Stevia leaves are a rich source of bioactive secondary metabolites, including flavonoids, phenolic acids like chlorogenic acid, and essential oils, which contribute to its potent antioxidant capacity.

4. Pharmacokinetics: Absorption, Metabolism, and Excretion

Steviol glycosides are not hydrolyzed by human digestive enzymes and pass intact through the upper gastrointestinal tract. Upon reaching the colon, they are extensively metabolized by the gut microbiota into steviol, which is subsequently absorbed, conjugated in the liver to form steviol glucuronide, and excreted primarily in urine.

Steviol glycosides enter the colon intact, where they undergo microbial degradation by members of the Bacteroidaceae family, resulting in the release of steviol, which is absorbed and metabolized to steviol glucuronide, and excreted primarily via the urine in humans. Experiments have confirmed that a range of steviol glycosides, including stevioside, Reb A, Reb B, Reb C, Reb D, Reb E, Reb F, Reb M, dulcoside A, and the stevioside dimer, are all completely hydrolyzed into the final product, steviol, by gut microbiota within 24–48 hours. This metabolic process shows no significant differences based on gender or ethnicity.

Humans cannot metabolize the glycosides in stevia, and it therefore has zero calories.

5. Established Mechanisms of Action

Insulinotropic Mechanism

The insulinotropic effects of stevioside and steviol were critically dependent on the prevailing glucose concentration; stevioside (1 mmol/L) and steviol (1 μmol/L) only potentiated insulin secretion at or above 8.3 mmol/L glucose. Interestingly, the insulinotropic effects of both stevioside and steviol were preserved in the absence of extracellular Ca²⁺. During perifusion of islets, stevioside (1 mmol/L) and steviol (1 μmol/L) had a long-lasting and apparently reversible insulinotropic effect in the presence of 16.7 mmol/L glucose.

Neither stevioside (1 to 100 μmol/L) nor steviol (10 nmol/L to 10 μmol/L) influenced the plasma membrane K⁺ adenosine triphosphate (KATP⁺)-sensitive channel activity, nor did they alter cyclic adenosine monophosphate (cAMP) levels in isolated islets. This distinguishes their mechanism from that of classic sulfonylurea drugs.

TRPM5 is a Ca²⁺-activated cation channel expressed in type II taste receptor cells and pancreatic β-cells. Stevioside, rebaudioside A, and their aglycon steviol potentiate the activity of TRPM5. Steviol glycosides potentiate perception of bitter, sweet, and umami taste, and enhance glucose-induced insulin secretion in a TRPM5-dependent manner. Daily consumption of stevioside prevents development of high-fat-diet-induced diabetic hyperglycaemia in wild-type mice, but not in Trpm5⁻/⁻ mice. These results elucidate a molecular mechanism of action of steviol glycosides and identify TRPM5 as a potential target to prevent and treat type 2 diabetes.

Findings from pharmacological research suggest that steviol glycosides have potent antidiabetic activity by mimicking insulin actions by regulating the PI3K/AKT pathway.

Antihypertensive Mechanism

In contrast to a relatively high degree of evidence supporting the hypoglycemic and insulinotropic effects of steviol glycosides and the mechanism thereof, evidence for the exact mechanism underlying the hypotensive effect is lacking. However, it has been reported that the antihypertensive mechanism of stevioside depends on the inhibition of Ca²⁺-influx from extracellular fluid. Other in vitro studies concluded that isosteviol, derived from stevioside, inhibited angiotensin-II and cell proliferation in the smooth muscle of rats. Isosteviol also reduced vasopressin-induced contraction in isolated aortic rings by means of opening the KATP and SKCa channels.

6. Scientific Evidence by Area of Use

6.1 Blood Glucose Regulation and Type 2 Diabetes

The most clinically studied area for steviol glycosides is their effect on glycemic control. Evidence comes from multiple randomized controlled trials (RCTs) and systematic reviews, though results are mixed.

A 2019 systematic review and meta-analysis (Anker et al., Aarhus University) critically evaluated evidence for the effectiveness of steviol glycosides on human health, particularly type 2 diabetic biomarkers, collecting data from RCTs. Seven studies comprising nine RCTs and a total of 462 participants were included. A meta-analysis assessed the effect of steviol glycosides on BMI, blood pressure (BP), fasting blood glucose (FBG), lipids, and HbA1c. The meta-analysis revealed an overall significant reduction in systolic BP in favour of steviol glycosides (mean difference: −6.32 mm Hg). The overall effect on BMI, diastolic BP, FBG, total cholesterol, and HDL-C was a non-significant reduction in favour of steviol glycosides, while no significant effect on HbA1c was found.

A separate, more recent meta-analysis found a small but statistically significant effect on fasting glucose: a significant effect of steviol glycosides on fasting blood glucose (MD = −4.10 mg dL⁻¹, 95% CI −6.55 to −1.65) was found, while no significant difference in HbA1c (MD = 0.01%, 95% CI −0.12% to 0.13%) was observed between steviol glycosides and controls. The overall quality of evidence was rated as low. Subgroup analyses demonstrated favorable effects of steviol glycosides on fasting blood glucose in participants aged ≤50 years, those without diabetes mellitus or hypertension at baseline, and overweight and obese adults. Evidence from RCTs showed an inconclusive effect of steviol glycosides on glucose metabolism in adult participants; twelve RCTs with a total of 871 participants (48% females) were included for analyses.

One pivotal clinical trial that directly examined Rebaudioside A found no pharmacological effect: this trial evaluated the effects of 16 weeks of consumption of 1,000 mg rebaudioside A (n=60) compared to placebo (n=62) in men and women (33–75 years of age) with type 2 diabetes mellitus. Mean changes in glycosylated hemoglobin levels did not differ significantly between the rebaudioside A (0.11 ± 0.06%) and placebo (0.09 ± 0.05%; p=0.355) groups. Changes in fasting glucose, insulin, and C-peptide did not differ significantly. Assessments of changes in blood pressure, body weight, and fasting lipids indicated no differences by treatment.

A separate pilot RCT at sweetener-level doses likewise found no pharmacological effect: subjects were randomly allocated to active treatment (the steviol glycoside stevioside: 250 mg three times daily) or to placebo and followed up for 3 months. Post-treatment systolic BP, diastolic BP, glucose, and glycated hemoglobin (HbA1c) were not significantly different from baseline measurements. No side effects were observed in the two treatment groups. This study showed that oral steviol glycosides taken as sweetener are well tolerated and have no pharmacological effect.

Evidence strength summary: The evidence from published RCTs suggests that stevioside may generate reductions in blood pressure and fasting blood glucose. The sizes of the effects are small, and the substantial heterogeneity limits the robustness of any conclusions. Overall, the clinical evidence for glucose-lowering effects in humans is preliminary and inconsistent, with low-quality evidence ratings.

6.2 Blood Pressure and Cardiovascular Effects

Several longer-term trials, primarily conducted with higher therapeutic doses of stevioside (not sweetener doses), have reported antihypertensive effects. Beneficial effects of high doses of steviol glycosides on hyperglycemia and hypertension have been previously described when these abnormalities are present.

In vitro and in vivo studies showed that stevia has antiglycemic action and antioxidant effects in adipose tissue and the vascular wall, reduces blood pressure levels and hepatic steatosis, stabilizes the atherosclerotic plaque, and ameliorates liver and kidney damage.

The antioxidant effect of stevia on both adipose tissue and the vascular wall induces plaque stabilization while inhibiting atherosclerotic plaque development. The stevia plant and its steviol glycosides appear to be an attractive source for anti-inflammatory agents, expanding applications beyond metabolic disorders such as diabetes and cardiovascular diseases.

Evidence strength summary: Blood-pressure effects observed in RCTs have been primarily at doses higher than typical dietary sweetener use. The 2019 meta-analysis found a significant systolic BP reduction, but heterogeneity between studies was marked. At sweetener-level doses, pharmacological BP effects were not confirmed.

6.3 Gut Microbiota Modulation

Due to the lack of randomized clinical trials in humans, this area of research has relied on in vitro studies using certain microbial strains and in vivo animal studies. Results indicated that stevia consumption has a potential benefit on the microbiome's alpha diversity. Alterations in the colonic microenvironment may depend on the amount and frequency of stevia intake, as well as on the simultaneous consumption of other dietary components.

In vitro tests, steviol glycosides did not exhibit any impact on bacterial growth. Data indicate that chronic exposure to steviol glycosides has no relevant impact on the gut microbiome, a pertinent fact not only from a safety viewpoint, but also from a pharmacokinetic perspective, as gut microbiota is fundamental for steviol absorption.

Evidence strength summary: The evidence for meaningful modulation of human gut microbiota by steviol glycosides remains preliminary. Most evidence is in vitro or animal-based, and results are inconsistent. Well-designed human RCTs are lacking in this area.

6.4 Anti-inflammatory and Antioxidant Effects

Pharmacological reviews indicate that steviol glycosides have a diverse range of activities, including antioxidant, anti-inflammatory, antiobesity, antihypertensive, antimicrobial, antidiarrheal, gastroprotective, hepatoprotective, pulmoprotective, and renoprotective activities. However, many of these findings are from preclinical (in vitro or animal) research. Scientific reports on the antidiabetic activity of stevia and its derivatives have shown inconsistent results, due to using different fractions of stevia or its extracts or compounds, doses, duration of treatment, as well as the experimental models (in vitro, in vivo, animal study, human trials).

Evidence strength summary: Anti-inflammatory and antioxidant properties have predominantly been demonstrated in preclinical settings. Translating these findings to clinical human outcomes requires more rigorous RCT data.

6.5 Oral Health / Dental Caries

Steviol glycosides are noncaloric, noncariogenic, and nonfermentative. Because they resist fermentation by oral bacteria — the process that produces the acid responsible for tooth decay — their use as a sugar substitute carries no cariogenic risk. This property is well-established physicochemically and is recognized by regulatory and scientific bodies.

6.6 Body Weight and Obesity

Several experimental studies have shown that stevia-derived compounds may have a broad spectrum of health-promoting properties, including anti-inflammatory, antihyperglycaemic, anti-parasitic, antioxidant, and antiviral potential. Recent studies have also reported that stevia-derived compounds and extracts may have a therapeutic effect in disorders associated with excess body weight and dyslipidaemia. However, as established by the 2019 meta-analysis, the overall effect of steviol glycosides on BMI in RCTs was a non-significant reduction. Evidence at this time does not confirm meaningful body weight effects in humans from steviol glycoside consumption at dietary levels.

7. Body Systems and Health Areas Associated with Steviol Glycosides

• Endocrine / Metabolic system: Steviol glycoside compounds possess medicinal activities including antidiabetic, antihypertensive, anti-inflammatory, antioxidant, anticancer, and antidiarrheal activity.
• Cardiovascular system: Studied in relation to blood pressure reduction and vascular antioxidant effects, primarily in preclinical models and a limited number of clinical trials using therapeutic doses.
• Gastrointestinal system: The metabolism of steviol glycosides is dependent upon gut microbiota, which breaks down glycosides into steviol that can be absorbed by the host.
• Oral health: Recognized as noncariogenic due to resistance to fermentation by oral microflora.
• Pancreatic beta-cell function: Glucose-dependent insulinotropic effects have been demonstrated in vitro and in animal models via TRPM5 channel potentiation.

8. Dosage Forms and Dosages Reported in Studies

The following dosages reflect those specifically reported in clinical research; they are not recommendations.

• In one RCT, the active treatment dose was stevioside at 250 mg, administered three times daily (t.d.s.) for 3 months.
• A 16-week RCT used 1,000 mg of rebaudioside A daily in men and women with type 2 diabetes mellitus (n=60 active, n=62 placebo).
• The established Acceptable Daily Intake (ADI) set by EFSA and JECFA for steviol glycosides is 4 mg per kg body weight per day, expressed as steviol equivalents.
• In the EU, steviol glycosides (E 960a–d) are authorised as a food additive in 32 different food categories with maximum permitted levels ranging from 20 to 3,300 mg steviol equivalents per kg.

Steviol glycosides are commercially available as tabletop sweetener tablets or powders, liquid drops, and as food/beverage additives. Clinical studies have primarily used oral preparations in capsule or liquid form.

9. Safety Considerations and Interactions

Regulatory Safety Status

Stevia, a zero-calorie sugar substitute, is recognized as safe by the Food and Drug Administration (FDA) and the European Food Safety Authority (EFSA). The safety of steviol glycosides as a food additive was evaluated by EFSA in 2010, and an ADI of 4 mg per kg body weight per day, expressed as steviol equivalents, was established, based on application of a 100-fold uncertainty factor to the no observed adverse effect level (NOAEL) from a 2-year carcinogenicity study in rats.

The Joint FAO/WHO Expert Committee on Food Additives (JECFA) reviewed the safety of steviol glycosides at four separate meetings (51st, 63rd, 68th, and 69th) in 1998, 2004, 2007, and 2008, and established specifications and an ADI for stevia extract as a high-potency sweetener.

Genotoxicity and Carcinogenicity

In 2006, after analysis of several studies carried out on stevia and steviol glycosides in humans and animals, the World Health Organization (WHO) stated: "stevioside and rebaudioside A are not genotoxic in vitro or in vivo and that the genotoxicity of steviol and some of its oxidative derivatives in vitro is not expressed in vivo."

National and international food safety agencies and approximately 20 expert panels have concluded that steviol glycosides, including the widely used sweeteners stevioside and rebaudioside A, are not genotoxic. The current database of in vitro and in vivo studies for steviol glycosides is robust and does not indicate that either stevioside or rebaudioside A are genotoxic. This, combined with a lack of evidence for neoplasm development in rat bioassays, establishes the safety of steviol glycosides with respect to their genotoxic/carcinogenic potential.

Toxicological testing showed that the substances are not genotoxic, nor carcinogenic, nor linked to any adverse effects on the reproductive human system or for the developing child.

Allergy

No food allergy related to stevia consumption as a sweetener has been reported since 2008, when high-purity steviol glycosides were introduced to the market. It is worth noting that Stevia rebaudiana belongs to the Asteraceae (Compositae) family, which also includes ragweed, chrysanthemums, marigolds, and daisies — plants known to trigger allergic reactions in sensitive individuals. Cross-reactivity in individuals with Asteraceae hypersensitivity has been discussed theoretically, though reports with high-purity commercial preparations are absent from the literature reviewed here.

High-Dose Renal Considerations

Experimental studies that investigated renal elimination detected nephrotoxicity in rats after subcutaneous administration of stevioside at 1.5 g/kg (equivalent to approximately 250 times the average daily human consumption). Increased urinary glucose and plasma creatinine levels were reported after stevioside administration. Stevioside apparently interferes with secretory transport systems at very high doses. These effects were observed at doses far exceeding the established ADI and are not considered relevant to typical dietary or supplemental use.

ADI Exceedance in Children

The EFSA Panel points out that the ADI of 4 mg/kg body weight per day could be exceeded by both adults and children if steviol glycoside sweeteners are used at the maximum levels proposed by manufacturers. With respect to proposed extensions of use and increases in maximum permitted levels, the EFSA Panel concluded that the calculated, conservative, dietary exposure would result in an increased exceedance of the ADI for toddlers at the 95th percentile.

Potential Interactions

Based on the pharmacological evidence reviewed, the following interactions warrant attention:

• Antidiabetic drugs: Given the glucose-dependent insulinotropic effects of stevioside documented at higher doses, concurrent use with insulin or insulin secretagogues (e.g., sulfonylureas) in patients with diabetes may theoretically augment glucose-lowering effects, though clinical evidence on this interaction is limited.
• Antihypertensive drugs: Beneficial effects of high doses of steviol glycosides on hypertension have been previously described. Additive effects with antihypertensive agents are theoretically possible at therapeutic doses, but evidence at sweetener-level doses does not confirm blood pressure effects in normotensive individuals.
• Drug transport: Further studies of secretory-transport-system inhibition are needed in order to establish whether stevioside could delay drug clearance in the human body.

Evidence Gaps and Limitations

The described bioactivities of steviol glycosides deserve special attention based on their dose dependence and specific pathological situations. Further clinical research is needed to understand underlying mechanisms of action, therapeutic indexes, and pharmacological applications. Whereas in some cases clinical studies have been conducted — prominently to investigate hypoglycemic and antihypertensive activity — many have failed to meet the expectations raised by preclinical investigations.

References

• Li et al. (2024). "Properties, extraction and purification technologies of Stevia rebaudiana steviol glycosides: A review." ScienceDirect.
• Wikipedia: Steviol glycoside
• Munteanu et al. (2023). "Steviol Glycosides from Stevia rebaudiana: An Updated Overview of Their Sweetening Activity, Pharmacological Properties, and Safety Aspects." Molecules. PMC9920402.
• Frontiers in Nutrition (2026). "The progress on stevia (Stevia rebaudiana Bertoni): chemical composition, pharmacokinetics, pharmacological effects, safety, applications, and biosynthesis."
• PMC (2025). "Discovery of Novel Minor Steviol Glycoside from the Stevia rebaudiana: Structural Characterization and Proposed Biosynthetic Pathway of Rebaudioside D17."
• Wikipedia: Stevia
• Anker et al. (2019). "Effect of Steviol Glycosides on Human Health with Emphasis on Type 2 Diabetic Biomarkers: A Systematic Review and Meta-Analysis of Randomized Controlled Trials." Nutrients. PMC6770957.
• PubMed (2024). "Effect of steviol glycosides as natural sweeteners on glucose metabolism in adult participants." (Systematic Review and Meta-Analysis.)
• Barriocanal et al. (2008). "Apparent lack of pharmacological effect of steviol glycosides used as sweeteners in humans. A pilot study." PubMed PMID 18397817.
• Wheeler et al. (2008). "Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus." PubMed PMID 18555575.
• Onakpoya & Heneghan (2015). "Effect of the natural sweetener, steviol glycoside, on cardiovascular risk factors: a systematic review and meta-analysis of randomised clinical trials." DARE / NCBI Bookshelf.
• Lemus-Mondaca et al. (2022). "The Effects of Stevia Consumption on Gut Bacteria: Friend or Foe?" PMC9028423.
• Gardana et al. (2020). "Metabolic fate in adult and pediatric population of steviol glycosides produced from stevia leaf extract by different production technologies." ScienceDirect.
• Philippaert et al. (2017). "Steviol glycosides enhance pancreatic beta-cell function and taste sensation by potentiation of TRPM5 channel activity." PMC5380970.
• Jeppesen et al. (2000). "Stevioside acts directly on pancreatic β cells to secrete insulin: Actions independent of cyclic adenosine monophosphate and adenosine triphosphate—sensitive K⁺-channel activity." Metabolism.
• EFSA (2010). "EFSA evaluates the safety of steviol glycosides."
• EFSA (2023). "Safety evaluation of the food additive steviol glycosides, predominantly Rebaudioside M, produced by fermentation using Yarrowia lipolytica VRM." EFSA Journal.
• EFSA (2024). "Scientific opinion on the extension of the authorisation of use of the food additive steviol glycosides (E 960a–d) and the modification of the ADI." PMC11533382.
• Urban et al. (2013). "Steviol glycoside safety: is the genotoxicity database sufficient?" PubMed PMID 23103588.
• Nikitin (2008). "A critical review of the genetic toxicity of steviol and steviol glycosides." PubMed PMID 18556105.
• Lemus-Mondaca et al. (2016). "A Review on the Pharmacology and Toxicology of Steviol Glycosides Extracted from Stevia rebaudiana." PubMed PMID 27784241.
• Ferdous et al. (2025). "Therapeutic Effects of Natural Food Additives Steviol Glycosides From Stevia rebaudiana: A Comprehensive Review With Mechanisms." Journal of Food Biochemistry.
• EFSA (2022). "Safety evaluation of glucosylated steviol glycosides as a food additive in different food categories." PMC8826121.
• JSTOR Daily: "Stevia's Global Story." (Referencing Chesterton & Yang.)
• Shahane et al. (2020). "'Sweeter' than its name: anti-inflammatory activities of Stevia rebaudiana." Journal of Herbs, Spices & Medicinal Plants. Taylor & Francis.